

Table of Content	Page
Figure S1. Incubation of VLC-derived fractions (fractions 1 to 8) at 100 µg/mL with <i>Pseudomonas aeruginosa</i> PAO1 <i>lasB-gfp</i> biosensor strain.	2
Figure S2. Mass spectra of VLC-derived fraction 3 (A) and fraction 4 (B) obtained by ESI-TOF-MS in positive ion mode, overlaid with the LC-UV chromatogram (light green lines).	2
Table S1. Mass spectral data and compound dereplication with the MarinLit database for compounds found in the LCMS analysis of fraction 3.	3
Table S2. SMILE notation and InChI code for 2 .	3
Figure S3. UV and HR-QTOF MS spectra of 2 .	4
Figure S4. ¹ H NMR spectrum of 2 in CDCl ₃ .	4
Figure S5. ¹³ C NMR spectrum of 2 in CDCl ₃ .	5
Figure S6. DEPT spectra of 2 in CDCl ₃ .	6
Figure S7. HSQC NMR spectrum of 2 in CDCl ₃ .	7
Figure S8. COSY NMR spectrum of 2 in CDCl ₃ .	8
Figure S9. HMBC spectrum of 2 in CDCl ₃ .	9
Figure S10. NOESY spectrum of 2 in CDCl ₃ .	10
Figure S11. Molecular docking of (A) natural ligand, <i>N</i> -3-oxo-dodecanoyl- <i>L</i> -homoserine lactone, (B) pitinoic acid A (8), (C) dysidazirine carboxylic acid (9) and (D) majusculoic acid onto LasR-ligand binding domain performed on Swissdock.	11




Figure S1. Incubation of VLC-derived fractions (fractions 1 to 8) at 100 $\mu\text{g/mL}$ with *Pseudomonas aeruginosa* PAO1 *lasB-gfp* biosensor strain. GFP/OD₆₀₀ values over a span of 17.5 h. DMSO, LasB, and ABTGC were used as negative, bacteria and media controls, respectively. The assay was conducted in triplicate at an effective concentration of 100 $\mu\text{g/mL}$. A lower GFP/OD₆₀₀ indicates better QS inhibition. Fractions 3 to 5 demonstrated the best QS inhibition and are represented by the thicker lines.




Figure S2. Mass spectra of VLC-derived fraction 3 (A) and fraction 4 (B) obtained by ESI-TOF-MS in positive ion mode, overlaid with the LC-UV chromatogram (light green lines).

Table S1. Mass spectral data and compound dereplication with the MarinLit database for metabolites found in the LCMS analysis of fractions 3 and 4.

Fraction	RT (min)	Measured Mass [M+H] ⁺	Predicted MF [M+H] ⁺	Err (in ppm)	Database search (Marinlit and Antibase)	Ref
3	5	279.0938	C ₂₀ H ₁₁ N ₂	-4.4	Pukeleimide A or B	[1]
4	5.9	379.2435	C ₁₇ H ₃₅ N ₂ O ₇	1.1	No hit	
3	6.4	261.1457	C ₁₁ H ₂₁ N ₂ O ₅	-4.9	No hit	
4	7.0	271.2247	C ₁₆ H ₃₁ O ₃	6.1	Malyngolide	[2]
3	7.1	347.2190	C ₁₇ H ₂₇ N ₆ O ₂	-0.3	No hit	
3	7.4	349.2345	C ₁₇ H ₂₉ N ₆ O ₂	0.4	No hit	
3	7.7	429.1603	C ₂₁ H ₃₄ BrO ₄	0.8	No hit	
3	7.9	331.2240	C ₁₆ H ₃₁ N ₂ O ₅	-1.6	Phomopsidin	[3]
3	9.8	257.2468	C ₁₆ H ₃₃ O ₂	2.0	(-)-trans-7S-methoxytetradec-4-enoic acid	[4]
3, 4	9.8	609.2685	C ₃₅ H ₃₇ N ₄ O ₆	3.7	No hit	
3, 4	9.8	637.3001	C ₃₇ H ₄₁ N ₄ O ₆	2.3	No hit	
3	10.3	537.4872	C ₃₂ H ₅₇ O ₆		No hit	
3, 4	10.4	623.2858	C ₃₆ H ₃₉ N ₄ O ₆	0.7	Pheophorbide-like compound	[5]
3, 4	10.8	607.2916	C ₃₆ H ₃₉ N ₄ O ₅	-0.1	No hit	
4	11.3	321.3128	C ₂₂ H ₄₁ O	5.0	No hit	

- Cardellina, J.H.; Moore, R. E. The structures of pukeleimides A, B, D, E, F, and G. *Tetrahedron Lett.* **1997**, *20*, 2007–2010.
- Cardellina, J.H.; Moore, R.E.; Arnold, E.V.; Clardy, J. Structure and absolute configuration of malyngolide, an antibiotic from the marine blue-green alga *Lyngbya majuscula* Gomont. *J. Org. Chem.* **1979**, *44*, 4039–4042.
- Namikoshi, M.; Kobayashi, H.; Yoshimoto, T.; Hosoya, T. Phomopsidin, a new inhibitor of microtubule assembly produced by phomopsis sp.. isolated from coral reef in Pohnpei. *J. Antibiot.* **1997**, *50*, 890–892.
- Cardellina, J.H.; Dalietos, D.; Marner, F.-J.; Mynderse, J.S.; Moore, R.E. (-)-trans-7(s)-methoxytetradec-4-enoic acid and related amides from the marine cyanophyte *Lyngbya majuscula*. *Phytochemistry* **1978**, *17*, 2091–2095.
- Ohta, S.; Ono, F.; Shiomi, Y. et al. Anti-herpes simplex virus substances produced by the marine green alga, *Dunaliella primolecta*. *J. Appl. Phycol.* **1998**, *10*, 349–356.

Table S2. SMILE notation and InChI code for **2**.

SMILE	CCCCCCC[C@@H]1C[C@H]1CCC(OC/C=C/C(Br)=C)=O
InChI	1/C18H29BrO2/c1-3-4-5-6-7-10-16-14-17(16)11-12-18(20)21-13-8-9-15(2)19/h8-9,16-17H,2-7,10-14H2,1H3/b9-8+/t16-,17-/m1/s1/i1-12,2-12,3-12,4-12,5-12,6-12,7-12,8-12,9-12,10-12,11-12,12-12,13-12,14-12,15-12,16-12,17-12,18-12,19-79,20-16,21-16




Figure S3. (A) UV and (B) HR-QTOF MS spectra of 2.





Figure S4. ^1H NMR spectrum of 2 in CDCl_3 .




Figure S5. ^{13}C NMR spectrum of **2** in CDCl_3 .





Figure S6. DEPT spectra of **2** in CDCl₃.




Figure S7. HSQC NMR spectrum of **2** in CDCl_3 .




Figure S8. COSY NMR spectrum of **2** in CDCl_3 .




Figure S9. HMBC spectrum of **2** in CDCl₃.




Figure S10. NOESY spectrum of **2** in CDCl_3 .




Figure S11. Molecular docking of (A) natural ligand, *N*-3-oxo-dodecanoyl-*L*-homoserine lactone, (B) pitinoic acid A (8), (C) dysidazirine carboxylic acid (9) and (D) majusculoic acid onto LasR-ligand binding domain performed on Swissdock.